Follow up Discussion : How to Take an Oncology Drug into the Clinic
Following our highly popular webinar, How to Take an Oncology Drug Into the Clinic, Senior Medical Director at Simbec-Orion, Dr Romillie Cruz talked with Professor Sarah Blagden, Professor of Medical Oncology, at the University of Oxford about some of the topics raised during the presentation.
- Role of the ECMC ( Experimental Cancer Medicine Centres) network in the UK, and how to work with the ECMC network to support clinical trial delivery
- The benefits of working with sites with a high number of referrals
- How referral networks work for satellite centres in the UK
- How ‘tumour networks’ work in the UK to facilitate patient recruitment
- How a well-designed, robust protocol specific to the IMP can support more flexible inclusion/ exclusion criteria
- How to optimise your protocol to support investigators
- The benefits of early involvement of investigators, KOLs and scientific advisors before protocol finalisation
- Importance of realistic thresholds to reflect the current health and present treatment options of cancer patients for a particular indication.
- Whilst phase I is largely biomarker-driven, for phase II – what are investigators looking for when assessing if a particular treatment is promising to treat the indication?
- Value of PK data in supporting clinical development
- What are the key takeaways when considering implementing complex, innovative (adaptive) clinical trial design in oncology?
- Benefits of adopting innovative trial design as a more economical, flexible option
- Lessons learned during the pandemic – how being more selective with patient data collection can support more patient-centric trial design and reduce costs
Access on-demand here